Alzamend Neuro, Inc.

Biotechnology • Healthcare • Atlanta, GA, United States • ALZN (NCM)

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - Yahoo Finance

Yahoo Finance • Jul 23

Ault Milton C III sells Alzamend Neuro (ALZN) stock worth $296k - Investing.com

Investing.com • Oct 6

Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan

Stock Titan • Nov 19

Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq

Nasdaq • Dec 22

Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN) - The Globe and Mail

The Globe and Mail • Dec 25

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Alzamend Neuro, Inc. had layoffs?

No layoff events have been recorded for Alzamend Neuro, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Alzamend Neuro, Inc. have?

Alzamend Neuro, Inc. has approximately 4 employees.

What industry is Alzamend Neuro, Inc. in?

Alzamend Neuro, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Alzamend Neuro, Inc. a publicly traded company?

Yes, Alzamend Neuro, Inc. is publicly traded under the ticker symbol ALZN on the NCM. The company has a market capitalization of approximately $0.01 billion.

Where is Alzamend Neuro, Inc. headquartered?

Alzamend Neuro, Inc. is headquartered in Atlanta, GA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.